December 07, 2025 02:24 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Centre imposes temporary fare caps as ticket prices defy gravity amid IndiGo meltdown | 'Action is coming': Aviation Minister blames IndiGo for countrywide air travel chaos | In front of Putin, PM Modi makes bold statement on Russia-Ukraine war: ‘India is not neutral, we side with peace!’ | Rupee weakens following RBI repo rate cut | RBI slashes repo rate by 25 basis points — big relief coming for borrowers! | 'Mamata fooled Muslims': Humayun Kabir explodes after TMC suspends him over 'Babri Masjid-style mosque' demand; announces new party | Mosque in the middle of Kolkata airport? Centre confirms flight risks, BJP fires at Mamata | Sam Altman is betting big on India! OpenAI in advanced talks with Tata to build AI infrastructure | Government removes mandatory pre-installation of Sanchar Saathi App. Know all details | Calcutta HC overturns controversial Bengal job annulment — 32,000 teachers rejoice!

Novartis to cut 680 jobs in product development: Report

| @indiablooms | Apr 10, 2024, at 02:40 am

New Delhi: Swiss pharmaceutical company Novartis said on Tuesday that it plans to reduce its development organization workforce by as many as 680 positions, media reports said.

Nearly 440 of these jobs will be cut in Switzerland and up to 240 in the United States within the next two to three years, reported Reuters.

These reductions are separate from a larger restructuring initiative that may result in up to 8,000 job cuts from Novartis's total global workforce of 78,000, the report said.

In a similar move, Roche, a competitor based in Switzerland, disclosed earlier in the year its decision to eliminate 345 positions from its product development sector.

Currently, Novartis employs around 12,500 individuals in development roles, covering responsibilities such as drug regulation, analytics, and support functions like quality assurance.

These personnel are also engaged in shaping the production processes for drugs following the completion of research activities.

About 3,000 of these positions are situated in Switzerland and 2,000 in the United States, indicating that approximately 14% of roles in these countries will be impacted.

However, Novartis plans to introduce new positions over the coming two to three years, resulting in an overall net reduction of 1-2% globally, the Reuters report said.

The company stated that these changes aim to reconfigure its capabilities to tap into local talent pools, including data scientists and regulatory specialists in Britain.

Despite the workforce adjustments, Novartis affirmed its dedication to development endeavours in both Switzerland and the United States.

According to the Reuters report, a company spokesperson said, "We remain committed to development in Switzerland as our innovation hub for complex development, and providing strategic leadership as the global headquarters for development.

"The US remains a key development hub with strong representation in our global program teams, responsible for advancing our medicines pipeline."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm